Background: Evaluation of the protein osteopontin (OPN) as a potential new marker in comparison to melanoma inhibitory activity (MIA) for screening and detection of metastatic uveal melanoma. Methods: Plasma levels of 32 patients with uveal melanoma were analyzed for OPN and MIA by enzyme-linked immunosorbent assay (ELISA). Fourteen of these patients had clinically detectable liver metastases. Results: Median plasma concentration of OPN in patients with metastatic disease was 152.01 ng/ml compared to 47.39 ng/ml in patients without clinically detectable metastases (p < 0.001). The difference between the median MIA plasma levels in patients with (13.11 ng/ml) and patients without (5.64 ng/ml) metastatic disease was also statistically signifi...
The mortality for uveal melanoma remains high because of the development of metastatic disease, pred...
Uveal melanoma (UM) is the most frequent primary intraocular tumor in adult humans. Despite the sign...
International audienceBACKGROUND: Despite the completion of numerous phase II studies, a standard of...
Background: Evaluation of the protein osteopontin (OPN) as a potential new marker in comparison to m...
Uveal melanoma (UM) continues to be associated with a high mortality rate of up to 50% due to metast...
Background While the serological tumour marker S100 is well established for the detection of metasta...
AIM: Our purpose was to determine whether S-100B or melanoma inhibitory activity (MIA) concentration...
Abstract Background Approximately 50% of uveal melanoma (UM) patients develop metastases preferentia...
Uveal melanoma metastases are lethal and remain incurable. A quantitative proteomic analysis of 53 m...
PURPOSE: We previously identified the presence of the melanocyte-specific secreted (ME20-S) glycopro...
Uveal melanoma (UM) is an ocular tumor with a dismal prognosis. It is the most frequent primary intr...
Uveal melanoma (UM) is the most common malignant intraocular tumour in the adult population. It is a...
<div><p>Background</p><p>Uveal melanoma is the most common malignancy of the adult eye. The overall ...
Overexpression of osteopontin (OPN) is strongly associated with the invasiveness/metastasis of many ...
Background: Osteopontin (OPN) is associated with human cancers, and circulating blood OPN may have d...
The mortality for uveal melanoma remains high because of the development of metastatic disease, pred...
Uveal melanoma (UM) is the most frequent primary intraocular tumor in adult humans. Despite the sign...
International audienceBACKGROUND: Despite the completion of numerous phase II studies, a standard of...
Background: Evaluation of the protein osteopontin (OPN) as a potential new marker in comparison to m...
Uveal melanoma (UM) continues to be associated with a high mortality rate of up to 50% due to metast...
Background While the serological tumour marker S100 is well established for the detection of metasta...
AIM: Our purpose was to determine whether S-100B or melanoma inhibitory activity (MIA) concentration...
Abstract Background Approximately 50% of uveal melanoma (UM) patients develop metastases preferentia...
Uveal melanoma metastases are lethal and remain incurable. A quantitative proteomic analysis of 53 m...
PURPOSE: We previously identified the presence of the melanocyte-specific secreted (ME20-S) glycopro...
Uveal melanoma (UM) is an ocular tumor with a dismal prognosis. It is the most frequent primary intr...
Uveal melanoma (UM) is the most common malignant intraocular tumour in the adult population. It is a...
<div><p>Background</p><p>Uveal melanoma is the most common malignancy of the adult eye. The overall ...
Overexpression of osteopontin (OPN) is strongly associated with the invasiveness/metastasis of many ...
Background: Osteopontin (OPN) is associated with human cancers, and circulating blood OPN may have d...
The mortality for uveal melanoma remains high because of the development of metastatic disease, pred...
Uveal melanoma (UM) is the most frequent primary intraocular tumor in adult humans. Despite the sign...
International audienceBACKGROUND: Despite the completion of numerous phase II studies, a standard of...